The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | The challenge of treatment resistance in patients with advanced EGFR-mutated NSCLC
Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, elaborates on how treatment resistance is an issue for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Dr Zhou highlights the importance of developing novel drugs and treatment strategies to combat this resistance and what effect this might have on extending progression-free survival in patients with advanced NSCLC. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
